Glucosylceramide administration as a vaccination strategy in mouse models of cryptococcosis
V Mor, AM Farnoud, A Singh, A Rella, H Tanno, K Ishii… - PloS one, 2016 - journals.plos.org
Cryptococcus neoformans is an opportunistic fungal pathogen and the causative agent of
the disease cryptococcosis. Cryptococcosis is initiated as a pulmonary infection and in …
the disease cryptococcosis. Cryptococcosis is initiated as a pulmonary infection and in …
Monoclonal Antibody to Fungal Glucosylceramide Protects Mice against Lethal Cryptococcus neoformans Infection
ML Rodrigues, L Shi, E Barreto-Bergter… - Clinical and Vaccine …, 2007 - Am Soc Microbiol
Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans
virulence. In the present study, we demonstrate that passive immunization with a …
virulence. In the present study, we demonstrate that passive immunization with a …
Cryptococcus neoformans Glucuronoxylomannan and Sterylglucoside Are Required for Host Protection in an Animal Vaccination Model
AC Colombo, A Rella, T Normile, LS Joffe, PM Tavares… - MBio, 2019 - Am Soc Microbiol
Cryptococcus neoformans is an encapsulated fungal pathogen that causes
meningoencephalitis. There are no prophylactic tools for cryptococcosis. Previously, our …
meningoencephalitis. There are no prophylactic tools for cryptococcosis. Previously, our …
Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis
SK Chow, A Casadevall - Vaccine, 2011 - Elsevier
Galactoxylomannan (GalXM) is a complex polysaccharide produced by the human
pathogenic fungus Cryptococcus neoformans that mediates profound immunological …
pathogenic fungus Cryptococcus neoformans that mediates profound immunological …
Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens
MM Hester, CK Lee, A Abraham, P Khoshkenar… - Vaccine, 2020 - Elsevier
Meningitis due to Cryptococcus neoformans is responsible for upwards of 180,000 deaths
worldwide annually, mostly in immunocompromised individuals. Currently there are no …
worldwide annually, mostly in immunocompromised individuals. Currently there are no …
Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts
CA Specht, CK Lee, H Huang, DJ Tipper, ZT Shen… - MBio, 2015 - Am Soc Microbiol
ABSTRACT A vaccine capable of protecting at-risk persons against infections due to
Cryptococcus neoformans and Cryptococcus gattii could reduce the substantial global …
Cryptococcus neoformans and Cryptococcus gattii could reduce the substantial global …
Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development
A Rella, V Mor, AM Farnoud, A Singh… - Frontiers in …, 2015 - frontiersin.org
Cryptococcosis caused by Cryptococcus neoformans and Cryptococcus gattii affects a large
population and is a cause of significant morbidity and mortality. Despite its public health …
population and is a cause of significant morbidity and mortality. Despite its public health …
[HTML][HTML] Cryptococcus neoformans Δsgl1 Vaccination Requires Either CD4+ or CD8+ T Cells for Complete Host Protection
TG Normile, A Rella, M Del Poeta - Frontiers in Cellular and Infection …, 2021 - frontiersin.org
Cryptococcus neoformans is a fungal pathogen causing life-threatening
meningoencephalitis in susceptible individuals. Fungal vaccine development has been …
meningoencephalitis in susceptible individuals. Fungal vaccine development has been …
[HTML][HTML] Three models of vaccination strategies against cryptococcosis in immunocompromised hosts using heat-killed Cryptococcus neoformans Δsgl1
TG Normile, M Del Poeta - Frontiers in Immunology, 2022 - frontiersin.org
Vaccines are one of the greatest medical accomplishments to date, yet no fungal vaccines
are currently available in humans mainly because opportunistic mycoses generally occur …
are currently available in humans mainly because opportunistic mycoses generally occur …
[PDF][PDF] Vaccination with recombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and …
CA Specht, CK Lee, H Huang, MM Hester, J Liu… - 2017 - core.ac.uk
Development of a vaccine to protect against cryptococcosis is a priority given the enormous
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …